Benolea ^® is a patented olive leaf extract standardized to 16-24 % oleuropein, which acts on GLP-1 receptors. The extract has been clinically proven to reduce blood glucose levels.[11]

Cinnamon bark is said to mimic the action of insulin and has been clinically proven to lower blood sugar levels through

Inulin, or long-chain fiber from chicory, can act as a probiotic, i.e., as food for good bacteria in the gut. It swells in water and is difficult to digest, which could reduce glucose intake from food. Because it swells and acts on GLP-1 receptors, it also increases the feeling of satiety.

FibregumTM is a protected form of acacia extract. It is a long fiber that could act like inulin.

Fibregum™ – long fiber from acacia, Benolea® – patented clinically tested olive leaf extract standardized to 16-24 % oleuropein, inulin, cinnamon bark extract, orange flavoring, acidity regulator: citric acid, red beet concentrate, anti-caking agent: tricalcium phosphate, beta carotene, and sweetener: sucralose.

Net quantity:
79.95 g (15 bags x 5.33 mg)

II. Premium supplement with clinically tested olive leaf extract, cinnamon bark, inulin, and long-chain acacia fiber

Over the past 50 years, a more sedentary lifestyle has become prevalent, characterized by reduced physical activity and increased consumption of meat, dairy products, vegetable oils, tobacco, sweet foods, sweetened beverages, and alcoholic beverages. In 2013, 382 million adults worldwide had diabetes, rising to 463 million in 2019, with 4.2 million people dying from diabetes in 2019.

II.A. Problems of poor metabolism

Diabetes is a group of medical conditions (metabolic syndrome, prediabetes, type 1 and type 2 diabetes, gestational diabetes) that affect the production, release, and use of insulin and can have various causes and mechanisms.

Hyperglycemia (too much sugar in the blood) and hyperlipidemia (too much fat in the blood) cause oxidative stress, amyloid accumulation in the pancreas, and chronic inflammation, leading to the destruction and dysfunction of β cells in the pancreas that release insulin.

II.A.1. Oxidative stress

Hyperglycemia and hyperlipidemia cause oxidative stress, which inhibits the mobilization of calcium Ca²⁺ in the pancreas (which should trigger insulin).

II.A.2. Amyloid accumulation

Hyperglycemia and hyperlipidemia also lead to the accumulation of amyloids in the pancreas. Amyloids are proteins that fold incorrectly due to oxidative stress, making them useless to the body. They accumulate in the pancreas and are believed to be one of the main causes of β-cell destruction.

II.A.3. Increased inflammation

In this process, β-cells are also subject to inflammation. In inflammation, the body's immune system attacks pathogens, but in chronic inflammation, it also attacks its own healthy cells. This chronic inflammation leads to the destruction of β-cells.

Non-functional β-cells do not respond to high levels of glucose and fat, or respond inadequately. As a result, they do not release enough insulin and glucose remains in the blood and organs, causing complications. Diabetes and similar conditions are a serious problem and require medical attention.

II.B. Scientific, in vitro, in vivo and the clinically proven effects of oleuropein and Benolea olive leaf extract®

 In vitro Studies are laboratory studies on cells or tissues. Each active substance is further studied in vitro, and excerpts from these studies form the basis for animal studies (in vivo), which form the basis for clinical studies (on humans). In vitro and in vivo Studies do not yet indicate that the same effect will occur in humans; they are primarily intended to determine the mechanism of action.

II.B.1. Oleuropein may reduce oxidative stress

In vitro It has been proven that oleuropein protects lipids, i.e. short-chain fats, from oxidation. It has also been in vitro proved that oleuropein protects β-cells from oxidative stress. This could potentially inhibit the production of amyloids in the body.

And vivo It was then demonstrated that oleuropein also protects other antioxidants, specifically vitamins A, E, and C.

It has been clinically proven that oleuropein reduces markers of oxidative stress in humans.

II.B.2. Oleuropein may reduce inflammation

In vivo have demonstrated that oleuropein reduces markers of inflammation.

II.B.3. Oleuropein may enhance the action of GLP-1 peptides, thereby increasing insulin and satiety.

GLP-1 (glucagon-like peptide 1) is a hormone that regulates insulin and the feeling of satiety. Medications for diabetics, such as Ozempic, act specifically on GLP-1. It has been clinically proven that oleuropein increases GLP-1 in the body and reduces blood sugar after meals.

II.B.4. Benolea® clinically proven to reduce blood glucose levels

Benolea reduced blood glucose levels from 8.4 to 7.9 mmol/L 30 minutes after a meal and from 8.6 to 7.8 mmol/L 60 minutes after a meal.

II.C. Cinnamon is a natural insulin mimic

In vitro have shown that polyphenols from cinnamon and cinnamon bark have a similar effect to insulin.

Clinical studies have shown that cinnamon lowers blood glucose, even by up to 25 %. As a result, the European Food Safety Authority (EFSA) has approved the claim that cinnamon helps regulate blood sugar.

II.D. Inulin, long fibers from chicory, and FibregumTM, long fibers from acacia, can increase the feeling of satiety.

Inulin, or long-chain fiber from chicory, is a type of fiber that is difficult to digest, so the body does not use it. However, it can feed good bacteria and swell in water. The idea is that when this fiber swells in the intestine, it regulates the intake of glucose from food into the body. This effect is also thought to work through its influence on the hormone GLP-1. The European Food Safety Authority (EFSA) therefore allows the claim that inulin helps increase the feeling of satiety. Long-chain fiber from chicory, Fibregum, may work in the same way.^TM.